-
1.发明公开公开(公告)号：US20230348582A1
公开(公告)日：2023-11-02
申请号：US18142242
申请日：2023-05-02
Applicant: Novo Nordisk A/S
Inventor： Anette Henriksen , Thomas Nylandsted Krogh , Per J. Greisen , Thomas Egebjerg
CPC classification number: C07K16/22 , A61P3/10 , A61K2039/505
Abstract: The present invention relates to novel monovalent anti-ANGPTL3 antibodies for use in medicine and in particular for lowering of plasma triglycerides levels in patients in need thereof, such as patients suffering from or at risk of hypertriglyceridemia and/or cardiovascular disease, such as atherosclerotic cardiovascular disease (ASCVD) as well as pharmaceutical compositions suitable for subcutaneous administration and kits comprising such compounds and compositions.
-
2.发明申请公开(公告)号：US20170190775A1
公开(公告)日：2017-07-06
申请号：US15372600
申请日：2016-12-08
Applicant: Novo Nordisk A/S
Inventor： Vibeke Westphal STENNICKE , Christine Brender Read , Susanne Nedergaard Grell , Charlotte Wiberg , Rune SaIbo , Anette Henriksen , Soeren Padkjaer
IPC: C07K16/28
CPC classification number: C07K16/2803 , A61K2039/505 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/75 , C07K2317/76 , C07K2317/92
Abstract: The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
-
3.发明申请ANTIBODIES THAT BIND AND BLOCK TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS-1 (TREM-1) 有权在MYELOID细胞-1（TREM-1）上表达的结合和阻断触发受体的抗体公开(公告)号：US20130211050A1
公开(公告)日：2013-08-15
申请号：US13690748
申请日：2012-11-30
Applicant: NOVO NORDISK A/S
Inventor： Vibeke Westphal Stennicke , Christine Brender Read , Susanne Nedergaard Grell , Charlotte Wiberg , Rune Salbo , Anette Henriksen , Soeren Padkjaer
IPC: C07K16/28
CPC classification number: C07K16/28 , A61K2039/505 , C07K16/2803 , C07K16/2896 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/567 , C07K2317/74 , C07K2317/76 , C07K2317/92
Abstract: The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
Abstract translation: 本发明涉及能够特异性结合TREM-1并防止TREM-1的活化的抗体，TREM-1是在单核细胞，巨噬细胞和嗜中性粒细胞上表达的蛋白质。 这种抗体可用于治疗具有炎性疾病的个体，例如类风湿性关节炎和炎症性肠病。
-
公开(公告)号：US10189904B2
公开(公告)日：2019-01-29
申请号：US15372600
申请日：2016-12-08
Applicant: Novo Nordisk A/S
Inventor： Vibeke Westphal Stennicke , Christine Brender Read , Susanne Nedergaard Grell , Charlotte Wiberg , Rune Salbo , Anette Henriksen , Soeren Padkjaer
IPC: A61K39/395 , C07K16/00 , C07K16/18 , C07K16/28 , A61K39/00
Abstract: The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
-
5.发明申请公开(公告)号：US20180105590A9
公开(公告)日：2018-04-19
申请号：US15372600
申请日：2016-12-08
Applicant: Novo Nordisk A/S
Inventor： Vibeke Westphal STENNICKE , Christine Brender Read , Susanne Nedergaard Grell , Charlotte Wiberg , Rune SaIbo , Anette Henriksen , Soeren Padkjaer
IPC: C07K16/28
CPC classification number: C07K16/2803 , A61K2039/505 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/75 , C07K2317/76 , C07K2317/92
Abstract: The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
-
Patent Agency Ranking
6.发明授权Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1) 有权在骨髓细胞-1（TREM-1）上表达的结合和阻断触发受体的抗体公开(公告)号：US09000127B2
公开(公告)日：2015-04-07
申请号：US13690748
申请日：2012-11-30
Applicant: Novo Nordisk A/S
Inventor： Vibeke Westphal Stennicke , Christine Brender Read , Susanne Nedergaard Grell , Charlotte Wiberg , Rune Salbo , Anette Henriksen , Soeren Padkjaer
IPC: A61K39/395 , C07K16/00 , C07K16/18 , C07K16/28 , A61K39/00
CPC classification number: C07K16/28 , A61K2039/505 , C07K16/2803 , C07K16/2896 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/567 , C07K2317/74 , C07K2317/76 , C07K2317/92
Abstract: The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
Abstract translation: 本发明涉及能够特异性结合TREM-1并防止TREM-1的活化的抗体，TREM-1是在单核细胞，巨噬细胞和嗜中性粒细胞上表达的蛋白质。 这种抗体可用于治疗具有炎性疾病的个体，例如类风湿性关节炎和炎症性肠病。
-
公开(公告)号：US10179814B2
公开(公告)日：2019-01-15
申请号：US15325865
申请日：2015-07-17
Applicant: NOVO NORDISK A/S
Inventor： Anette Henriksen , Kristian Kjærgaard , Vibeke Westphal Stennicke , Charlotte Wiberg
IPC: C07K16/28
Abstract: Antibodies that are capable of specifically binding and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils with both good affinity and low viscosity at clinically relevant concentrations are described. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
-
8.发明申请NOVEL RECEPTOR TREM (TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS) AND USES THEREOF 审中-公开新生受体TREM（在MYELOID细胞上表达的触发受体）及其用途公开(公告)号：US20160251434A1
公开(公告)日：2016-09-01
申请号：US14616470
申请日：2015-02-06
Applicant: Novo Nordisk A/S
Inventor： Marco Colonna , Axel Bouchon , Rune Salbo , Charlotte Wiberg , Vibeke Westphal Stennicke , Anette Henriksen , Mette Dahl Andersen
IPC: C07K16/28
CPC classification number: C07K16/2803 , C07K14/70503 , C07K16/28 , C07K2317/76
Abstract: Novel activating receptors of the lg super-family expressed on human myeloid cells, called TREM(s) (triggering receptor expressed on myeloid cells) are provided. Specifically, two (2) members of TREMs, TREM-1 and TREM-2 are disclosed. TREM-1 is a transmembrane glycoprotein expressed selectively on blood neutrophils and a subset of monocytes but not on lymphocytes and other cell types and is upregulated by bacterial and fungal products. Use of TREM-1 in treatment and diagnosis of various inflammatory diseases is also provided. TREM-2 is also a transmembrane glycoprotein expressed selectively on mast cells and peripheral dendritic cells (DCs) but not on granulocytes or monocytes. DC stimulation via TREM-2 leads to DC maturation and resistance to apoptosis, and induces strong upregulation of CCR7 and subsequent chemotaxis toward macrophage inflammatory protein 3-β. TREM-2 has utility in modulating host immune responses in various immune disorders, including autoimmune diseases and allergic disorders.
Abstract translation: 提供了称为TREM（在骨髓细胞上表达的触发受体）的人类骨髓细胞上表达的lg超家族的新型活化受体。 具体地说，公开了TREMs，TREM-1和TREM-2的两（2）个成员。 TREM-1是一种在血液嗜中性粒细胞和单核细胞亚群上有选择性表达而不是淋巴细胞和其他细胞类型的跨膜糖蛋白，并被细菌和真菌产品上调。 还提供了TREM-1在各种炎性疾病的治疗和诊断中的应用。 TREM-2也是在肥大细胞和外周树突状细胞（DC）上选择性表达但不在粒细胞或单核细胞上表达的跨膜糖蛋白。 通过TREM-2的DC刺激导致DC成熟和抗凋亡，并且诱导CCR7的强烈上调和随后对巨噬细胞炎症蛋白3-β的趋化性。 TREM-2可用于调节各种免疫疾病中的宿主免疫应答，包括自身免疫性疾病和过敏性疾病。
-
9.发明申请Antibodies that Bind and Block Triggering Receptor Expressed on Myeloid Cells-1 (TREM-1) 审中-公开绑定和阻断触发受体表达于骨髓细胞-1（TREM-1）的抗体公开(公告)号：US20150274825A1
公开(公告)日：2015-10-01
申请号：US14632079
申请日：2015-02-26
Applicant: Novo Nordisk A/S
Inventor： Vibeke Westphal Stennicke , Christine Brender Read , Susanne Nedergaard Grell , Charlotte Wiberg , Rune Salbo , Anette Henriksen , Soeren Padkjaer
IPC: C07K16/28
CPC classification number: C07K16/28 , A61K2039/505 , C07K16/2803 , C07K16/2896 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/567 , C07K2317/74 , C07K2317/76 , C07K2317/92
Abstract: The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
Abstract translation: 本发明涉及能够特异性结合TREM-1并防止TREM-1的活化的抗体，TREM-1是在单核细胞，巨噬细胞和嗜中性粒细胞上表达的蛋白质。 这种抗体可用于治疗具有炎性疾病的个体，例如类风湿性关节炎和炎症性肠病。
-
10.发明授权公开(公告)号：US11780910B1
公开(公告)日：2023-10-10
申请号：US18142242
申请日：2023-05-02
Applicant: Novo Nordisk A/S
Inventor： Anette Henriksen , Thomas Nylandsted Krogh , Per J. Greisen , Thomas Egebjerg
CPC classification number: C07K16/22 , A61P3/10 , A61K2039/505 , C07K2317/35 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: The present invention relates to novel monovalent anti-ANGPTL3 antibodies for use in medicine and in particular for lowering of plasma triglycerides levels in patients in need thereof, such as patients suffering from or at risk of hypertriglyceridemia and/or cardiovascular disease, such as atherosclerotic cardiovascular disease (ASCVD) as well as pharmaceutical compositions suitable for subcutaneous administration and kits comprising such compounds and compositions.
-
-
-
-
-
-
-
-
-
Search Results
19
records
(took 0.024 seconds)
